Applied Biosystems Inc.

Applied Biosystems — Applera — Merger or Acquisition (June 2008)

30 slides from Applied Biosystems's merger presentation, Jun 17, 2008

  1. Slide 1: Creating the Premier Provider of Biotechnology Reagents and Systems

    Creating the Premier Provider of Biotechnology Reagents and Systems June 12, 2008

  2. Slide 2: Forward-Looking Statements

    2 Certain statements contained in this presentations are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and Invitrogen and Applera intend that such forward-looking statements be subject to the safe harbor created thereby. Forward-looking stat

  3. Slide 3: Non-GAAP Measurements and Additional Information

    3 Non-GAAP Measurements This presentation and discussion includes certain financial information which constitute “non-GAAP financial measures” as defined by the SEC. The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most di

  4. Slide 4: Agenda

    4 Agenda Transaction Overview 1 Strategic Rationale 2 Financial Highlights 3 Next Steps 4

  5. Slide 5: Transaction Overview

    5 Transaction Overview Transaction Structure Consideration and Relative Ownership Approvals Company Name Headquarters Closing • Invitrogen will acquire all of the outstanding shares of Applied Biosystems for $38 per share in a combination of cash and stock, for a total value of $6.7 billion • Applie

  6. Slide 6: Transaction Overview (Continued): Board and Executive Management

    6 Board Composition Executive Management • 9 Invitrogen and 3 Applera board members Greg Lucier Chairman, President and CEO • Invitrogen CEO and Board Member since May 2003 • Invitrogen Chairman since April 2004 • Former Corporate Officer of General Electric Corporation David Hoffmeister Senior VP,

  7. Slide 7: Combining Industry Leaders

    7 Combining Industry Leaders • Founded: 1987 • Premier provider of consumable kits and reagents • Annual revenue of $1.3 billion • Leading positions in: – Cell Culture (GIBCO) – Labeling and Detection – Molecular Biology Kits • ~4,700 employees • 1,200 patents & licenses • Carlsbad, CA (HQ) • Founde

  8. Slide 8: Shared Vision: Advance Science to Improve the Human Condition

    8 Advance Science to Improve the Human Condition Shared Vision Innovate to Solve Customer Workflow Challenges Deliver Superior Quality and Reliability Differentiate the Customer Experience Win Together

  9. Slide 9: Newco Competitive Advantages

    9 Newco Competitive Advantages New Company Well-Positioned to Benefit From Macrotrends Genomics and cell biology convergence Translation of technologies to applied markets Race to understand human genome and genetic variations Growth in emerging geographies Positioned to capture more of profit strea

  10. Slide 10: Agenda

    10 Agenda Transaction Overview 2 Strategic Rationale 1 Financial Highlights 3 Next Steps 4

  11. Slide 11: Strategic Rationale

    11 • Highly complementary, best-in-class product offerings • Broad and extensive commercial network • Strong platform for expansion into high-growth markets • Significant value creation opportunities for shareholders • Strong financial profile Strategic Rationale Merger combines the industry's premi

  12. Slide 12: Best in Class Product Offerings Across All Major Biological Disciplines

    12 Best in Class Product Offerings Across All Major Biological Disciplines... • ChargeSwitch® nucleic acid prep • SYBR® Green • Gateway® & TOPO® cloning Gene Regulation Proteomics Cell Biology Genomics • SuperScript ® reverse transcription • Lipofectamine ® transfection • Novex® gels, stains, standa

  13. Slide 13: With Highly Complementary Revenue Streams

    13 With Highly Complementary Revenue Streams... Consumables & Services* 60% Mass Spec Instruments 19% Instrument Reagent Systems 21% Consumables & Services* 74% Mass Spec Instruments 12% Instrument Reagent Systems 14% Consumables & Services* 99% Instrument Reagent Systems 1% IVGN Revenues ABI Revenu

  14. Slide 14: New End-to-End Workflow Solutions

    14 Enables Combined Company to Create New End-to-End Workflow Solutions Sample Prep Detection / Analysis Data Interpretation Sample Processing • Innovate around workflows • Serve customers holistically

  15. Slide 15: Innovation Engine Supported by Significant Scale

    15 $112 $190 IVGN (1) ABI (2) Patents & Licenses 1,200 2,400 IVGN ABI R&D Investment (in millions) R&D Investment (% of revenue) 8.5% 11.4% IVGN ABI (2,3) (2) FY2008 Estimate (3) excludes mass spec revenue Leading investment in R&D provides significant scale for developing breakthrough innovations I

  16. Slide 16: Broad and Extensive Commercial Network with Complementary Skills

    16 • Excels at repeat business • e-Commerce expertise • 1,000+ supply centers • Strong relationships with bench scientists • Excels at systems sales • Global service infrastructure • Presence beyond life sciences • High level customer relationships • Approximately 3,000 sales & service personnel • F

  17. Slide 17: Strong Platform for Expansion Into High Growth Markets

    17 Market Size Market Growth Capabilities: Applied Markets $9B Low double digits Emerging Geographies $1B Midteen’s Cell Biology $6B High single digits Next Gen Sequencing >35% $200M Strong Platform for Expansion Into High Growth Markets

  18. Slide 18: Complete Solutions in Key Cell Biology Workflows

    18 New Company Will Have Capabilities to Offer Complete Solutions in Key Cell Biology Workflows $8.2B $6.3B 2010 2007 Key Growth Points: •Disease relevant cells and cell inputs •Stem cells and cell therapy •Multiplexing and bench top instrumentation 9% CAGR IVGN 63% Best Cell Biology Supplier: Marke

  19. Slide 19: Applied Markets Represent Attractive Growth Opportunity

    19 Applied Markets Represent Attractive Growth Opportunity 700 800 400 800 1,100 1,100 2,700 2,400 $9.2B 1,200 600 1,400 1,300 3,700 3,400 $12.4B 2010 Other Forensics QA / QC AgBio Food Safety Histology/Cytology Molecular Dx 2007 Source: Kalorama, Global Strategic Business, Frost and Sullivan, Consu

  20. Slide 20: Next Generation Sequencing Driving New Discoveries

    20 “Genomic Revolution” • Improved diagnostics & disease management • Transformed clinical trials right treatments for right patients • Genomic baseline at birth educated consumer and lifestyle choices improve human condition Next Generation Sequencing Driving New Discoveries SOLiD Platform • Highes

  21. Slide 21: Genomic Analysis Drives Downstream Revenue

    21 Increased validation by RT-PCR Genomic Analysis Drives Downstream Revenue SOLiD™ drives down the cost of rare SNP /expressor discovery Application to therapeutics /diagnostics Increase in cell biology research to understand gene products in context More questions

  22. Slide 22: Agenda

    22 Agenda Transaction Overview 3 Strategic Rationale 1 Financial Highlights 2 Next Steps 4

  23. Slide 23: Significant Opportunities for Value Creation

    23 • At least $125 million annual cost savings by 3rd year – Raw material synergies – Overhead redundancies – Facility rationalizaton – R&D scale • At least $50 million annual Operating Income from revenue synergies by 3rd year – Cross selling/channel synergies – Penetration of new markets – New joi

  24. Slide 24: Strong Financial Profile

    24 • ~$3.5 billion in combined LTM revenue • Strong EBITDA and operating cash flow contribution • Intent to quickly repay debt LTM March 31, 2008 $803 23% $480 22% $323 24% Operating Cash Flow as % of Revenue $859 25% $490 23% $369 28% EBITDA(1) as % of Revenue $3,496 $2,173 $1,323 Revenue ProForma

  25. Slide 25: Revenue Diversified Across Segments

    25 Revenue Diversified Across Segments... with a significant contribution from high-margin consumables Rev. By End Markets Rev. By Product Mix Industry & Other 20% Pharma & Biotech 30% Academic & Govt 50% Rev. By Geography United States 44% Europe 34% APAC 16% Other 6% Consumables & Services 74% Mas

  26. Slide 26: 2009 Financial Goals

    26 2009 Financial Goals $2.60+(2) Non-GAAP EPS (1) Mid single digits Organic Revenue Growth 2009E Notes: (1) Non-GAAP EPS excludes certain acquisition related costs, including amortization of intangible assets, business integration and other expenses. (2) Neutral to slightly accretive to 2009 Street

  27. Slide 27: Agenda

    27 Agenda Transaction Overview 4 Strategic Rationale 1 Financial Highlights 2 Next Steps 3

  28. Slide 28: Next Steps

    28 Next Steps • Approvals – Invitrogen and ABI shareholder approval – HSR, ECMR and other regulatory approval – Expected close: Fall of 2008 • Integration Roadmap – Project management team put in place immediately – Upon closing: • Reagent businesses combined quickly and smoothly • Instrument busine

  29. Slide 29: Experienced Management Teams Will Deliver on Deal Promise

    29 Experienced Management Teams Will Deliver on Deal Promise • Invitrogen team: – Executed upon significant improvements to financial profile in <2 years – >30% shareholder returns in last 5 years – Integrated 15 acquisitions in 3 years – On track to deliver 7th consecutive quarter of strong organic

  30. Slide 30: Strategic Rationale

    30 • Highly complementary, best-in-class product offerings • Broad and extensive commercial network • Strong platform for expansion into high-growth markets • Significant opportunities for value creation for shareholders • Strong financial profile Strategic Rationale Merger combines the industry's p

Applera — Merger or Acquisition (June 2008) on 6ix